A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADCT-402-105
Phase 1 other active
Quick answer
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma is a Phase 1 program (other) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active